for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover
Journal of Clinical and Experimental Hepatology
Journal Prestige (SJR): 0.971
Citation Impact (citeScore): 2
Number of Followers: 4  
  Full-text available via subscription Subscription journal
ISSN (Print) 0973-6883
Published by Elsevier Homepage  [3163 journals]
  • Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic
           Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and
           Meta-Analysis of Randomized Controlled Trials
    • Authors: Roger F. Butterworth; Gerald Kircheis, Norbert Hilger, Mark J.W. McPhail
      Abstract: l-Ornithine l-Aspartate (LOLA) is a mixture of two endogenous amino acids with the capacity to fix ammonia in the form of urea and/or glutamine. Its’ efficacy for the treatment of Hepatic Encephalopathy (HE), a known hyperammonemic disorder, remains the subject of debate. This study quantitatively analyzed the efficacy of LOLA in patients with cirrhosis and HE.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-06-11
      DOI: 10.1016/j.jceh.2018.05.004
  • Branched Amino Acids and Zinc in the Nutrition of Liver Cirrhosis
    • Authors: Kurt Grüngreiff
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-28
      DOI: 10.1016/j.jceh.2018.04.004
  • Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related
           Decompensated Cirrhosis
    • Authors: Naveen Tmu; Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora
      Abstract: Sofosbuvir (SOF), a direct acting antiviral, has revolutionized the treatment of chronic Hepatitis C Virus (HCV) infection. However, data is scarce about efficacy of SOF plus Ribavarin (RBV) in Indian patients with decompensated cirrhosis. We evaluated the efficacy of SOF plus RBV in decompensated cirrhosis, and compared the outcome with compensated cirrhosis and non-cirrhotics.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-26
      DOI: 10.1016/j.jceh.2018.02.009
  • Hepatic Encephalopathy and Astrocyte Senescence
    • Authors: Boris Görg; Ayşe Karababa, Dieter Häussinger
      Abstract: Hepatic Encephalopathy (HE) is a severe complication of acute or chronic liver diseases with a broad spectrum of neurological symptoms including motor disturbances and cognitive impairment of different severity. Contrary to former beliefs, a growing number of studies suggest that cognitive impairment may not fully reverse after an acute episode of overt HE in patients with liver cirrhosis. The reasons for persistent cognitive impairment in HE are currently unknown but recent observations raise the possibility that astrocyte senescence may play a role here.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-25
      DOI: 10.1016/j.jceh.2018.05.003
  • Systems Challenges of Hepatic Carcinomas: A Review
    • Authors: Dhatri Madduru; Johny Ijaq, Sujata Dhar, Saumyadip Sarkar, Naresh Poondla, Partha S. Das, Silvia Vasquez, Prashanth Suravajhala
      Abstract: Hepatocellular Carcinoma (HCC) is ubiquitous in its prevalence in most of the developing countries. In the era of systems biology, multi-omics has evinced an extensive approach to define the underlying mechanism of disease progression. HCC is a multifactorial disease and the investigation of progression of liver cirrhosis becomes much extensive with cultivating omics approaches. We have performed a comprehensive review about such challenges in multi-omics approaches that are concerned to identify the immunological, genetics and epidemiological factors associated with HCC.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-25
      DOI: 10.1016/j.jceh.2018.05.002
  • Chemical Analysis of Weight Loss Herbal Supplement Safe Lean™ Associated
           With Acute Liver Injury – A Concern for Spurious Drug, Misbranding and
    • Authors: Cyriac A. Philips; Philip Augustine
      Abstract: Liver injury due to herbal and dietary supplements are well described in literature and its incidence has been on the rise in the past decade. Labelling an herbal product as non-medicinal and as a supplement precludes protocols needed for testing, trials and marketing criteria. This has led to rampant use of clinically unproven multi-herb-based drugs use for a myriad of lifestyle diseases. In this report, we discuss a new dietary weight loss supplement, Safe Lean™ that was found to be the cause of liver injury in a young obese woman, that resolved after discontinuation, and discuss current literature on component, toxicology and chemical analysis of the offending drug.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-25
      DOI: 10.1016/j.jceh.2018.05.001
  • A/H1N1/09 Influenza is Associated With High Mortality in Liver Cirrhosis
    • Authors: Madhumita Premkumar; Devaraja Devurgowda, Shivani Dudha, Rakhi Maiwall, Chhagan Bihari, Shrruti Grover, Ekta Gupta, Sachin Kumar, Shiv K. Sarin
      Abstract: A/H1N1/09 influenza is associated with a high risk of complications in patients with chronic diseases. In view of patients with cirrhosis being recognized as another high-risk group for influenza morbidity and mortality, we report a cluster of suspected A/H1N1/09 infection in 110 patients admitted to a hepatology intensive care unit.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-25
      DOI: 10.1016/j.jceh.2018.04.006
  • Primary Hepatic Leiomyosarcoma: Histopathologist's Perspective of a Rare
    • Authors: Suvradeep Mitra; Sahaj Rathi, Uma Debi, Radha K. Dhiman, Ashim Das
      Abstract: Primary hepatic leiomyosarcoma is a rare primary mesenchymal tumor of the liver requiring exclusion of any other primary site of origin and histological and immunohistochemical exclusion of other hepatic/extrahepatic tumors with spindle cell morphology. Only about 70 cases are reported in the English literature and many of these tumors have predisposing conditions in the form of immunosuppression or associated malignancies. The occurrence of this tumor in the immunocompetent individual is also known.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-22
      DOI: 10.1016/j.jceh.2018.04.015
  • Management of Chronic Hepatitis B: Knowledge and Practices of Physicians
           in Pakistan
    • Authors: Qurat-ul-Ain Hafeez; Amna S. Butt, Furqaan Ahmed
      Abstract: In Pakistan, approximately 4.5 million people are afflicted with chronic hepatitis B (CHB). The compliance with hepatitis B virus (HBV) management guidelines is still unknown. This was the first study from Pakistan in which the knowledge and practices of treating physicians were compared with three standardized guidelines (Asia Pacific Association for the Study of the Liver (APASL) 2012/European Association for the Study of the Liver (EASL) 2012/American Association for the Study of Liver Diseases (AASLD) 2009).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-18
      DOI: 10.1016/j.jceh.2017.12.009
  • Methods for Studying Gut Microbiota: A Primer for Physicians
    • Authors: Aditya N. Sarangi; Amit Goel, Rakesh Aggarwal
      Abstract: Human gastrointestinal tract contains a large variety of microbes, in particular bacteria. Studies in recent years have strongly suggested a role for these microbes, collectively referred to as gut microbiota, in the maintenance of homeostasis during health. In addition, alterations in gut microbiota have been reported in several diseases, including those related to the gastrointestinal tract and several systemic conditions, and are believed to play a pathogenetic role in at least some of these.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-17
      DOI: 10.1016/j.jceh.2018.04.016
  • Hepatic Dysfunction in a Child Post Bone Marrow Transplantation
    • Authors: Vikrant Sood; Juhi Chawla, Bikrant B. Lal, Rajeev Khanna, Chhagan Bihari, Seema Alam
      Abstract: A 10-year-old female child, a known case of Beta-Thalassemia major with superimposed chronic Hepatitis C Viral (HCV) infection, underwent bone marrow transplantation and presented, 7 months later, with worsening hepatic functions and skin rash. Considering the wide variety of possible etiologies, she was evaluated and later confirmed as a case of hepatic dysfunction secondary to HCV related hepatic injury with concomitant chronic graft versus host disease (dermatological involvement only).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-15
      DOI: 10.1016/j.jceh.2018.04.014
  • Prognostic Implications of Minimal/Covert Hepatic Encephalopathy:
           Large-scale Validation Cohort Studies
    • Authors: Christopher R. Flud; Andres Duarte-Rojo
      Abstract: Minimal or Covert Hepatic Encephalopathy (MHE/CHE), the preclinical phase of Hepatic Encephalopathy (HE), is strongly associated with poorer Quality of Life (QOL), Overt HE (OHE), and death. Several diagnostic tests have been developed that have prognostic value in predicting clinical outcomes such as OHE, cirrhosis progression, and death. However, dispute among clinicians and HE researchers have kept its application largely underutilized. Current issues contributing to the confusion include: lack of a formal definition for CHE, uncertainty of which diagnostic tools to use, and whether one or two abnormal tests are required for a diagnosis.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-15
      DOI: 10.1016/j.jceh.2018.04.009
  • Rupture of Hepatocellular Carcinoma: A Review of Literature
    • Authors: Srimanta K. Sahu; Yogesh K. Chawla, Radha K. Dhiman, Virendra Singh, Ajay Duseja, Sunil Taneja, Naveen Kalra, Ujjwal Gorsi
      Abstract: Approximately 700,000 people die of Hepatocellular Carcinoma (HCC) each year worldwide, making it the third leading cause of cancer related deaths. Rupture is a potentially life-threatening complication of HCC. The incidence of HCC rupture is higher in Asia and Africa than in Europe. In Asia approximately 10% of patients with a diagnosis of HCC die due to rupture each year. Spontaneous rupture is the third most common cause of death due to HCC after tumor progression and liver failure. The diagnosis of rupture in patients without history of cirrhosis or HCC may be difficult.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-15
      DOI: 10.1016/j.jceh.2018.04.002
  • Delirium Tremens (DT): Assessment and Management
    • Authors: Sandeep Grover; Abhishek Ghosh
      Abstract: Delirium Tremens (DT) falls in the most severe spectrum of alcohol withdrawal, which could potentially result in death, unless managed promptly and adequately. The prevalence of DT in general population is
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-14
      DOI: 10.1016/j.jceh.2018.04.012
  • MHE Testing in Real World Scenario—A Mini-review
    • Authors: Mette M. Lauridsen; Hendrik Vilstrup
      Abstract: Professional MHE awareness is high but when it comes to psychometric testing for MHE the real world scenario is characterized by hesitation and testing is offered only to selected cirrhosis patients. The hesitation is rooted in doubts about which tests to use, lack of knowledge about treatment benefits, and uncertainty about the tests’ ability to identify patients who will benefit from anti-HE treatment. Thus, the majority of MHE patients do not receive the available efficient anti-HE treatment.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-14
      DOI: 10.1016/j.jceh.2018.04.010
  • Radiological Intervention for Shunt Related Encephalopathy
    • Authors: Silvia Nardelli; Stefania Gioia, Lorenzo Ridola, Oliviero Riggio
      Abstract: Hepatic Encephalopathy (HE) is a neuropsychiatric syndrome that occurs in up to 30% of patients with cirrhosis. HE may be a consequence of pure liver failure, as in patients with fulminant hepatitis, or of the combination of liver failure and portal-systemic shunting, as in patients with liver cirrhosis. Several clinical and pathophysiologic observations suggest the importance of portal-systemic shunts in the development of HE. Episodes of HE are usually related to precipitating events, such as infections or gastrointestinal bleeding; a minority of cirrhotic patients experienced a chronic HE, refractory to standard medical treatment.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-14
      DOI: 10.1016/j.jceh.2018.04.008
  • Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic
    • Authors: Barbara Lattanzi; Daria D’Ambrosio, Manuela Merli
      Abstract: Sarcopenia is an important burden in liver cirrhosis representing a negative prognostic factor for mortality. Moreover, sarcopenia is an independent predictor of complications in patients with liver cirrhosis, including Hepatic Encephalopathy (HE). An association between sarcopenia and HE in liver cirrhosis has been reported in recent studies, indeed both these complications often affect patients with advanced liver cirrhosis and may exert a synergic effect in deteriorating patients’ outcome. Episodes of HE occur more often in patients with muscle depletion.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-11
      DOI: 10.1016/j.jceh.2018.04.007
  • Neurological Monitoring in Acute Liver Failure
    • Authors: Mohammed F. Sheikh; Nazri Unni, Banwari Agarwal
      Abstract: Cerebral oedema and Intracranial Hypertension (ICH) are serious complications of acute liver failure affecting approximately 30% of patients, resulting in neurological injury or death. Multiple pathogenetic mechanisms contribute to the pathogenesis of HE including circulating neurotoxins such as ammonia, systemic and neuro-inflammation, infection and cerebral hyperaemia due to loss of cerebral vascular autoregulation. Early recognition and diagnosis is often difficult as clinical signs of elevated Intracranial Pressure (ICP) are not uniformly present and maybe masked by other organ support.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-10
      DOI: 10.1016/j.jceh.2018.04.013
  • Bile Acids in Hepatic Encephalopathy
    • Authors: Sharon DeMorrow
      Abstract: Hepatic encephalopathy describes the array of neurological complications that arise due to liver insufficiency and/or portal-systemic shunt. The pathogenesis of hepatic encephalopathy shares a longstanding association with hyperammonemia and inflammation. Recently, aberrant bile acid signaling has been implicated in the development of key features of hepatic encephalopathy due to acute liver failure including neuronal dysfunction, neuroinflammation and blood–brain barrier permeability. This review summarizes the findings of recent studies demonstrating a role for bile acids in hepatic encephalopathy and speculates on the possible downstream consequences of bile acid signaling.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-10
      DOI: 10.1016/j.jceh.2018.04.011
  • Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty
           Liver Disease
    • Authors: Alexander J. Kovalic; Pratik Banerjee, Quynh T. Tran, Ashwani K. Singal, Sanjaya K. Satapathy
      Abstract: Nonalcoholic Fatty Liver Disease (NAFLD) constitutes a wide spectrum of liver pathology with hepatic steatosis at the core of this pathogenesis. Variations of certain genetic components have demonstrated increased susceptibility for hepatic steatosis. Therefore, these inciting variants must be further characterized in order to ultimately provide effective, targeted therapies for NAFLD and will be the focus of this review. Several genetic variants revealed an association with NAFLD through Genome-wide Association Study, meta-analyses, and retrospective case–control studies.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-10
      DOI: 10.1016/j.jceh.2018.04.001
  • Cross-sectional Imaging of Gallbladder Carcinoma: An Update
    • Authors: Naveen Kalra; Pankaj Gupta, Manphool Singhal, Rajesh Gupta, Vikas Gupta, Radhika Srinivasan, Bhagwant R. Mittal, Radha K. Dhiman, Niranjan Khandelwal
      Abstract: Gallbladder Carcinoma (GBCA) is the most common biliary tract malignancy. As the disease is often diagnosed clinically in an advanced stage, the survival rates are dismal. Imaging studies allow for an early diagnosis of malignancy, though the findings may be indistinguishable from non-malignant disease processes affecting the gallbladder. Attempts have been made to make a specific diagnosis of GBCA at an early stage on imaging studies. Ultrasonography (US) is the most commonly employed technique for gallbladder evaluation.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-05-08
      DOI: 10.1016/j.jceh.2018.04.005
  • Percutaneous Transhepatic Approach for Recanalization of Superior
           Mesenteric and Portal Vein in a Patient With Pancreatic Neuroendocrine
           Tumor Presenting With Bleeding Duodenal Varices: A Brief Case Report
    • Authors: Ajit Yadav; Gaurav Gangwani, Nitin Mishra, Arun Gupta
      Abstract: Occlusion of Portal Vein (PV) and Superior Mesenteric Vein (SMV) is a known effect of local infiltration by pancreatic or mesenteric neuroendocrine tumors. Venous occlusion leads to formation of collateral pathways to restore hepatopetal flow in main PV and these collateral pathways can be seen in the form of ectopic (duodenal or jejunal) varices. We present a case of bleeding duodenal varices secondary to SMV occlusion by a locally infiltrating pancreatic neuroendocrine tumor which was successfully treated by coil embolization of varices and SMV stenting of the occluded venous segment after failure of endoscopic glue injection.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-13
      DOI: 10.1016/j.jceh.2018.03.003
  • Prevalence of Hepatitis B and C Viral Markers in Blood Donors Deferred
           from Donating Blood on the Basis of a History of Jaundice of Unknown
    • Authors: Chandra Prakash; Suchet Sachdev, Neelam Marwaha, Rekha Hans
      Abstract: The aim of the present study was to know the prevalence of viral hepatitis markers among blood donors deferred on the basis of a history of jaundice of unknown origin and to predict the impact of this deferral on blood safety.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-13
      DOI: 10.1016/j.jceh.2018.03.001
  • Immune-tolerant Chronic Hepatitis B Infection—Is the Liver Really
    • Authors: Sandeep Satsangi
      Abstract: The Indian National Association for Study of the Liver (INASL) constantly provides Indian consensus guidelines to manage various diseases affecting the liver. The INASL recently published its guidelines to manage patients with Hepatitis B Virus (HBV) infection in your esteemed journal and I would like to congratulate the authors on their commendable work.1
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-06
      DOI: 10.1016/j.jceh.2018.03.002
  • Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in
           Indian Patients
    • Authors: Gyanranjan Rout; Saurabh Kedia, Baibaswata Nayak, Rajni Yadav, Prasenjit Das, Subrat K. Acharya, Deepak Gunjan, Vishwajeet Singh, Mousumi Mahanta, Swatantra Gupta, Sandeep Aggarwal, Shalimar
      Abstract: The gold standard method for measurement of hepatic steatosis is liver histology. Controlled Attenuation Parameter (CAP) can measure hepatic steatosis non-invasively. We aimed to assess the accuracy of CAP for detection of hepatic steatosis.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-26
      DOI: 10.1016/j.jceh.2018.02.010
  • How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy
    • Authors: Lorenzo Ridola; Silvia Nardelli, Stefania Gioia, Oliviero Riggio
      Abstract: The design of clinical trials on Hepatic Encephalopathy (HE) is not an easy task, in fact there are several issues related to the performance of clinical trials in HE that have impeded progress in the field, mainly because most of the studies on HE therapy were performed before the era of rigorous Randomized Controlled Trials (RCTs). In this review we discuss the major problems affecting previously published trials on HE treatments aiming to provide evidences, suggestions and indications to prepare well designed RCTs in three different settings: (1) management of hospitalized patients with episodic HE; (2) secondary prophylaxis in patients following an episode of HE; and (3) management of minimal/covert HE.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-22
      DOI: 10.1016/j.jceh.2018.02.007
  • Long Term Survival of Patients Undergoing TIPS in Budd-Chiari Syndrome
    • Authors: Amey D. Sonavane; Deepak N. Amarapurkar, Krantikumar R. Rathod, Sundeep J. Punamiya
      Abstract: There has been significant improvement in understanding the etiology and management of Budd-Chiari Syndrome (BCS). Patients with chronic or acute-on-chronic BCS need radiological interventions in the form of angioplasty, hepatic vein/inferior vena cava stenting or Transjugular Intrahepatic Portosystemic Shunt (TIPS). Data regarding the long term follow up of patients undergoing TIPS is limited. We thus prospectively followed-up BCS patients who underwent TIPS at our center.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-10
      DOI: 10.1016/j.jceh.2018.02.008
  • Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C
           Virus (HCV) Glycoproteins: An in silico Approach
    • Authors: Anoop Kumar; Roma Pandey, Inderjit S. Yadav, Mausumi Bharadwaj
      Abstract: Chronic infection with Hepatitis C Virus (HCV) poses a major risk for liver disease like cirrhosis, liver failure and hepatocellular carcinoma. In terms of percentage, the prevalence of HCV in India was found to be low to moderate (1–1.5%), but in terms of sheer numbers, India has a significant number of global HCV patients. Presently, HCV can be treated with direct acting-antibody drugs but there is no prophylactic or therapeutic vaccine available against it. In HCV infection, T- and B-cell immunity is important for clearing the virus.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-03
      DOI: 10.1016/j.jceh.2017.12.010
  • Hepatitis B Virus Infection of Normal Hepatic Stem/Progenitor Cells
    • Authors: Wendy W. Bautista; Carla Osiowy, Julianne Klein, Gerald Y. Minuk
      Abstract: Whether the hepatitis B virus (HBV) infects normal hepatic stem/progenitor cells (NSCs) and if so, whether such infections play a role in the pathogenesis of HBV-induced chronic liver disease (CLD) and/or hepatocellular carcinoma (HCC) remains to be determined. The objectives of this study were to determine whether HBV infects NSCs and whether such infections alter NSC activity in a manner likely to contribute to the development of CLD and/or HCC.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-28
      DOI: 10.1016/j.jceh.2018.02.002
  • Prevalence of Nephrolithiasis in Patients with Chronic Liver Disease: A
           Case–Control Study
    • Authors: Ivan E. Porter; William C. Palmer, Alexander S. Parker, David O. Hodge, Nancy N. Diehl, William E. Haley
      Abstract: Nephrolithiasis is known to be associated with several systemic diseases including chronic kidney disease and renal failure, which can also occur as a complication of chronic liver disease (CLD). This study aimed to assess the prevalence of nephrolithiasis in patients with CLD.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-28
      DOI: 10.1016/j.jceh.2018.01.004
  • Potential Implications of Detecting HBsAg in Asymptomatic People in an
           Endemic Community Through Medical Camps
    • Authors: Gourdas Choudhuri; Varun Gupta, Tajinder Singh Negi, Rajesh Ojha
      Abstract: In a developing country like India with intermediate level of prevalence of hepatitis B, most of the patients remain undiagnosed as they are asymptomatic. The purpose of the study was to diagnose asymptomatic HBsAg positive patients from the general population and evaluate further the potential clinical implications of IDAHS.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-26
      DOI: 10.1016/j.jceh.2018.02.005
  • Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR)
           in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver
           Disease (NAFLD) as Serological Fibrosis Marker
    • Authors: Özlem Akdoğan; Ayşegül Atak Yücel, Zeynep Gök Sargin, Cemile Sönmez, Güldal Esendağli Yilmaz, Seren Özenirler
      Abstract: Progressive hepatic fibrosis is the main predictor of outcome and prognosis in chronic liver diseases. The importance of the coagulation cascade has been defined in liver fibrosis; however, the role of the fibrinolytic pathway has not been clear yet. We aimed to evaluate the association between the plasma levels of soluble urokinase Plasminogen Activator Receptor (uPAR) and the severity of liver fibrosis in chronic hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-26
      DOI: 10.1016/j.jceh.2018.02.001
  • The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of
           Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis
    • Authors: Osmanuddin Ahmed; Lisa Liu, Antony Gayed, Amanjit Baadh, Mikin Patel, Jordan Tasse, Ulku Turba, Bulent Arslan
      Abstract: The purpose of this research is to analyze the past and forecast the future prevalence of Hepatitis C Virus (HCV) and Nonalcoholic Steatohepatitis (NASH) and their respective contribution to Hepatocellular Carcinoma (HCC) incidence in the setting of novel anti-viral agents and rising obesity rates in the United States.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-24
      DOI: 10.1016/j.jceh.2018.02.006
  • De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A
           Series of 4 Cases
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Dheeraj Gautam, Neeraj Saraf, Arvinder S. Soin
      Abstract: While Autoimmune Hepatitis (AIH) may recur in patients after liver transplant, an AIH like presentation (positive auto antibodies, raised immunoglobulin G, raised transaminases and histology showing plasma cell rich infiltrate) may also occur in liver transplant recipients who had transplant for some other disease, called De novo Autoimmune Hepatitis (DAIH). A timely diagnosis and treatment can prevent further graft dysfunction. We report 4 cases of DAIH after living donor liver transplantation.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-24
      DOI: 10.1016/j.jceh.2018.02.004
  • Recovery of the Cholangiocytes After Ischemia and Reperfusion Injury:
           Ultra-Structural, Hystological and Molecular Assessment in Rats
    • Authors: Thiago P.A. Aloia; Bruno Cogliati, Janaina M. Monteiro, Anna C.K. Goldberg, Paolo R. de Oliveira Salvalaggio
      Abstract: Ischemia–reperfusion (I/R) injury of the liver is a common area of interest to transplant and hepatic surgery. Nevertheless, most of the current knowledge of I/R of the liver derives from the hepatocyte and little is known of what happens to the cholangiocytes. Herein, we assess the sequence of early events involved in the I/R injury of the cholangiocytes.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-23
      DOI: 10.1016/j.jceh.2018.01.003
  • Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa
    • Authors: Henry N. Luma; Servais A.F.B. Eloumou, Dominique N. Noah, B. Aude Eyenga, Georges Nko’Ayissi, T. Sylvie Taku, Agnes Malongue, Olivier Donfack-Sontsa, Ivo C. Ditah
      Abstract: Hepatitis C virus (HCV) infection is a major public health challenge in Cameroon with over three million people infected. Government efforts to improve care and treatment are unsatisfactory and need to be assessed. We aimed at studying the several steps along the HCV continuum of care in one of two hepatitis treatment centers in Cameroon.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-03
      DOI: 10.1016/j.jceh.2018.01.001
  • Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease: An Analysis
           of Risk Factors
    • Authors: Kaumudee Pattnaik; Pallavi Bhuyan, Ayaskant Singh, Shivaram P. Singh, Preetam Nath, Sanjib Kar, Bijay Misra, Jayashree Rath
      Abstract: Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of liver disease in India. NAFLD is characterized by hepatic steatosis in absence of a significant alcohol use or other known liver disease. Non-alcoholic steatohepatitis (NASH) is a progressive form of NAFLD which deserves particular attention because it is more prone for development of fibrosis. Liver biopsy is the gold standard for diagnosis of NASH by evaluating necroinflammatory activity and stages of fibrosis. The aim of the study was to analyze liver biopsy specimens and identify risk factors associated with fibrosis in patients of NAFLD in eastern coastal India.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-22
      DOI: 10.1016/j.jceh.2017.12.008
  • Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is
           Related to the Presence of Diabetes Mellitus and Severity of Liver Disease
    • Authors: Ram V. Nampoothiri; Ajay Duseja, Manish Rathi, Swastik Agrawal, Naresh Sachdeva, Manu Mehta, Harpal S. Dhaliwal, Radhakrishan Dhiman, Yogesh Chawla
      Abstract: There is sparse data on the prevalence of renal dysfunction in patients with nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the presence of renal dysfunction in patients with NAFLD and correlate it with the severity of liver disease.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-19
      DOI: 10.1016/j.jceh.2017.12.005
  • Incidence and Risk of Gallstone Disease in Gilbert's Syndrome Patients in
           Indian Population
    • Authors: Govardhan Bale; Urmila S. Avanthi, N.Rao Padaki, Mithun Sharma, N.Reddy Duvvur, V.Ravi Kanth Vishnubhotla
      Abstract: Individuals with Gilbert's syndrome (GS) harbor mutations in the UGT1A1 gene and are known to have elevated levels of bilirubin, which enhances the risk for gall stone formation. The aim of this study is to screen Indian patients with GS for the incidence of gall stone disease.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-15
      DOI: 10.1016/j.jceh.2017.12.006
  • Evaluation of Splenic Stiffness in Patients of Extrahepatic Portal Vein
           Obstruction Using 2D Shear Wave Elastography: Comparison with
           Intra-Operative Portal Pressure
    • Authors: Kumble S. Madhusudhan; Ragini Kilambi, Shalimar, Sujoy Pal, Raju Sharma, Deep N. Srivastava
      Abstract: To compare splenic stiffness (SS) with intra-operative portal pressures (PPs) in patients of extrahepatic portal vein obstruction (EHPVO).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-04
      DOI: 10.1016/j.jceh.2017.12.002
  • Race and Gradient Difference Are Associated with Increased Risk of Hepatic
           Encephalopathy Hospital Admission After Transjugular Intrahepatic
           Portosystemic Shunt Placement
    • Authors: Michael W. Rowley; Myunghan Choi, Steve Chen, Kevin Hirsch, Anil B. Seetharam
      Abstract: Hepatic encephalopathy (HE) is a well-recognized complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. The aim of this investigation was to evaluate incidence and predictors of post-TIPS HE necessitating hospital admission in a non-clinical trial setting.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-03
      DOI: 10.1016/j.jceh.2017.12.003
  • Outcome of Living Donor Liver Transplantation for Wilson's Disease in
           Adults: A Single Center Experience
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Neeraj Saraf, Amit Rastogi, Sanjay Goja, Prashant Bhangui, Srinivasan Thiagrajan, Dheeraj Gautam, Deepak Govil, Vijay Vohra, Arvinder S. Soin
      First page: 132
      Abstract: Although liver transplantation is a definitive cure for Wilson's disease (WD), there is limited data about results of living donor liver transplantation (LDLT) in adults.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-24
      DOI: 10.1016/j.jceh.2017.11.003
  • Hepatitis C Virus Infection and Vaccine Development
    • Authors: Xuan Guo; Jin-Yi Zhong, Jun-Wen Li
      First page: 195
      Abstract: In the twenty-seven years since the discovery of hepatitis C virus (HCV) the majority of individuals exposed to HCV establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In developed nations, the cure rates of HCV infection could be over 90% with direct-acting antiviral (DAA) regimens, which has made the great progress in global eradication. However, the cost of these treatments is so expensive that the patients in developing nations, where the disease burden is the most severe, could not afford it, which highly restricted its access.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-27
      DOI: 10.1016/j.jceh.2018.02.003
  • Cefazolin Induced Liver Injury and Hypoprothrombinemia
    • Authors: Ankur Gupta; Anil K. Singh, Khursheed Faridi, Priyanka Jain
      First page: 213
      Abstract: We encountered an uncommon adverse effect with cefazolin, a first generation cephalosporin in a young male with medulloblastoma. Cefazolin is a commonly used antibiotic for surgical prophylaxis.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-21
      DOI: 10.1016/j.jceh.2017.12.004
  • Leucopenia: A Rare Extrahepatic Manifestation of Acute Hepatitis A
    • Authors: Ankur Gupta; Priyanka Jain
      First page: 215
      Abstract: Hepatitis A infection is a common cause of viral hepatitis in developing world. It is acquired by feco-oral transmission. Patients usually have self-limited disease with uneventful recovery. Extrahepatic manifestations of acute hepatitis A are uncommon and include rash, arthralgias and other rare ones. Hematologic effects include thrombocytopenia and rarely red cell aplasia and aplastic anemia. We recently came across a case of a young female who presented with prodromal symptoms with isolated leucopenia.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-02
      DOI: 10.1016/j.jceh.2017.12.007
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-